Clinical trials: Prostate Cancer (Diagnosis)
Prostatic Neoplasms
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
The purpose of this study is to determine the relative bioavailability (rBA; Period 1) and bioequivalence (BE; Period 2 and 3) of various strengths and formulations of niraparib and abiraterone acetate (AA) at steady state under…
- Trial name
- NCT04577833
- Testing
- Niraparib, Abiraterone Acetate (AA), Prednisone
- Where
- 16 sites in United States, Belgium and 9 more
- Volunteers
- 136 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Castration-Resistant Prostate Cancer
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants…
- Trial name
- NCT06842498
- Testing
- FG-3246
- Where
- 23 sites in United States
- Volunteers
- 75 people
- Sponsor
- Kyntra Bio
Prostate Cancer
Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients
This is a Phase I, open-label, parallel design study of PAN-301-1 (SNS-301), a HAAH directed nanoparticle vaccine, given intradermally in cohorts of patients with biochemically relapsed prostate cancer, using a fixed dose…
- Trial name
- NCT03120832
- Testing
- PAN-301-1
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Prostatic Neoplasms
Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer
The purpose of this study is to evaluate how safe PS-341(VELCADE) is when given with Docetaxel (Taxotere) to patients with androgen-independent prostate cancer, and also to see what effects (good and bad) it has on you and on…
- Trial name
- NCT00064610
- Testing
- VELCADE TM (bortezomib) for Injection
- Where
- 4 sites in United States
- Volunteers
- 102 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies
The goal of this Phase 1/2a interventional study is to evaluate the safety and tolerability of CRG-150 in relapsed/refractory HR+HER2- breast cancer, Triple Negative Breast Cancer (TNBC) and prostate cancer.
- Conditions
- HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Prostate Cancer
- Trial name
- NCT07730125
- Testing
- CRG-150
- Volunteers
- 67 people
- Sponsor
- CoRegen, Inc.
Prostate Cancer
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.
- Trial name
- CheckMate 9KD (NCT03338790)
- Testing
- nivolumab, docetaxel, enzalutamide
- Where
- 66 sites in United States, Argentina and 9 more
- Volunteers
- 292 people
- Sponsor
- Bristol-Myers Squibb
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating…
- Trial name
- NCT00083213
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Prostate Cancer
A Trial of Degarelix in Patients With Prostate Cancer
A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.
- Trial name
- NCT00946920
- Testing
- Degarelix, Goserelin acetate
- Where
- 126 sites in United States, Belgium and 12 more
- Volunteers
- 859 people
- Sponsor
- Ferring Pharmaceuticals
Prostatic Neoplasms
Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
This is an exploratory research study with the aim of identifying specific cancer biomarkers in various subtypes of prostate cancer.
- Trial name
- NCT04964271
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tethis S.p.A.
Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
The purpose of this study is to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancer.
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer
- Trial name
- NCT04887506
- Testing
- TAVT-45, Zytiga, Prednisone
- Where
- 42 sites in United States, France and 6 more
- Volunteers
- 107 people
- Sponsor
- Tavanta Therapeutics
Metastatic Prostate Cancer
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.
- Trial name
- NCT05413421
- Testing
- ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 275 people
- Sponsor
- ORIC Pharmaceuticals
Non Small Cell Lung Cancer, Esophageal Cancer
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
- Conditions
- Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
- Trial name
- NCT05983432
- Testing
- BL-B01D1
- Where
- 37 sites in United States, France and 3 more
- Volunteers
- 540 people
- Sponsor
- SystImmune Inc.
Prostate Cancer
AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer
The present study will investigate the safety, tolerability and spectrum of side effects of AGS-1C4D4. As such, this study will characterize the dose limiting toxicities (DLT) and potentially the maximum tolerated dose (MTD) of…
- Trial name
- NCT00519233
- Testing
- AGS-1C4D4
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Astellas Pharma Inc
Prostatic Neoplasms
Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer
SGN-15 is being investigated for therapy of patients with prostate cancer in combination with the cytotoxic agent, Taxotere. The study is an open label, randomized phase II study for patients with documented hormone refractory…
- Trial name
- NCT00031187
- Testing
- SGN-15 (cBR96-doxorubicin immunoconjugate), Taxotere (docetaxel)
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- Seagen Inc.
Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a…
- Trial name
- NCT02123758
- Testing
- Abiraterone Acetate, Prednisone, JNJ-56021927
- Where
- 7 sites in United States, Canada and 2 more
- Volunteers
- 57 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic…
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT07545811
- Testing
- JANX014
- Where
- 6 sites in United States
- Volunteers
- 43 people
- Sponsor
- Janux Therapeutics
Castration Resistant Metastatic Prostate Cancer, Prostate Cancer
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity of…
- Conditions
- Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC
- Trial name
- BActinium-1 (NCT07581184)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- 8 sites in United States
- Volunteers
- 138 people
- Sponsor
- Aktis Oncology, Inc.
Solid Tumor, Adult, BRCA1 Mutation
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.
- Conditions
- Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
- Trial name
- NCT06380660
- Testing
- ACE-86225106 tablet
- Where
- 14 sites in China
- Volunteers
- 298 people
- Sponsor
- Acerand Therapeutics (Shanghai) Limited
Metastatic Prostate Cancer
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
The purpose of this study is to find the recommended doses of dasatinib and docetaxel given in combination to men with metastatic hormone refractory prostate cancer and to assess the pharmacokinetic interactions between the 2…
- Trial name
- NCT00439270
- Testing
- Dasatinib, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Bristol-Myers Squibb
Prostatic Neoplasms
Study to Assess the Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC)
The purpose of this study is to assess the treatment patterns in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- REALIST-PRO (NCT02230059)
- Testing
- No Intervention
- Where
- 10 sites in Brazil
- Volunteers
- 382 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.